Citations 2
P257 Efficacy and safety up to 3 years of risankizumab in moderately to severely active ulcerative colitis patients: COMMAND interim results
Atreya, Raja, Louis, Edouard, Loftus, Edward V, Rubin, David T, Dubinsky, Marla C., Hisamatsu, T, Kalabic, Jasmina , Méndez, Paloma, Chen, S H, Shah, Saajan, Morisset, Pierre, Duan, W Rachel, Coll, Christina, Panaccione, Remo, Atreya, Raja Narayana , Rubin, David T. , Hisamatsu, Tadakazu, Mendez, Paloma, Morisset, Pierre, Duan, W Rachel, Panaccione, Remo
E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A240.2-A241
Mirikizumab Demonstrates Long-Term Efficacy on Histological Resolution in the Phase 3, Multicenter, Open-Label VIVID-2 Extension Study
Reinisch, W, Jairath, V, Protic, M, Hertogh, G De, Harpaz, N, Hisamatsu, T, D'Haens, G, Pai, R, Morris, N, Hozak, R, Yu, G, Durand, F, Magro, F, Reinisch, W, Protić, Marijana , Hertogh, G De, Harpaz, Noam , Hisamatsu, Tadakazu, D’Haens, Geert , Pai, Rish, Morris, Nathan , Hozak, Rebecca R., Durand, Frédérick
Zeitschrift für Gastroenterologie | June 8, 2026 | Volume: 64 | Issue: 05 | Pages: e139-e140